Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
13
HSA:6
PHILIPPINES:6
FDA:1
Drug Approvals
Clinical Trials
No trials found
News
Rubicon Research Secures ₹250 Crore Pre-IPO Investment from Amansa, Reduces Fresh Issue Size Ahead of Year-End Public Listing
Amansa Investments has completed a ₹250 crore pre-IPO investment in pharmaceutical formulations company Rubicon Research, acquiring shares at ₹484.47 per share.